TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04166214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging using intraoral cameras
Description: The SOPROCARE is intended for clinical practice of general dentistry, as an aid in the diagnosis of pit and fissure caries, as an aid to highlight dental plaque and gingival inflammations and as intra-oral camera to visualize anatomical details that are invisible to the naked eye or with a mirror. In CARIO mode, the camera helps the dental practitioner to highlight carious warning on pits and fissures of the occlusal side of the teeth. In DAYLIGHT mode, the camera enables you to visualize anatomical details invisible to the naked eye or with a mirror. In PERIO mode, the camera helps the dental practitioner to see the presence of dental plaque but also to highlight gingival inflammations . This mode offers to the dentist and/or hygienist a tool for an improved communication, motivation and education of his/her patients, who will then become aware of their oral health condition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging using intraoral cameras
Description: The SOPROCARE is intended for clinical practice of general dentistry, as an aid in the diagnosis of pit and fissure caries, as an aid to highlight dental plaque and gingival inflammations and as intra-oral camera to visualize anatomical details that are invisible to the naked eye or with a mirror. In CARIO mode, the camera helps the dental practitioner to highlight carious warning on pits and fissures of the occlusal side of the teeth. In DAYLIGHT mode, the camera enables you to visualize anatomical details invisible to the naked eye or with a mirror. In PERIO mode, the camera helps the dental practitioner to see the presence of dental plaque but also to highlight gingival inflammations . This mode offers to the dentist and/or hygienist a tool for an improved communication, motivation and education of his/her patients, who will then become aware of their oral health condition.
Study: NCT00329108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone hydrochloride
Description: Ziprasidone will be initiated at 80 mg/day on Day 1 and titrated to 120 mg/day from Day 3. From Day 7 the dosage may be adjusted on the basis of clinical status between 120 and 160 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: Olanzapine will be started at 15 mg/day on Day 1 until Day 7. The dosage will then be adjusted on the basis of clinical status between 15 and 20 mg/day.
Study: NCT01094288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib ECT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel IV infusion
Study: NCT01389232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeriScaffold® Surgical Scaffold
Description: A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
Study: NCT03255187

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Description: Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in fish oil group are assigned to receive 2.5 g/day in divided doses. Each capsule contains 60% n-3 PUFA \[24% docosahexanoic acid (C22:6 n-3 DHA) and 36% eicosapentaenoic acid (C20:5 n-3 EPA)\].

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower seed oil supplementation
Description: Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in sunflower seed oil group receive 2.5 g/day in divided doses, and the capsules are identical as the fish oil capsules.
Study: NCT00613795

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus GG
Description: Every 12 hours, the contents of a single capsule containing Lactobacillus GG will be suspended in 3 ml of water-soluble jelly. The suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second capsule will be suspended in 10 ml of sterile water and pushed through the NG tub followed by 10 mL of air to ensure complete administration.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Every 12 hours, the contents of a single identical placebo capsule containing the inert plant carbohydrate inulin will be suspended in 3 ml of water-soluble jelly. This suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second placebo capsule will be suspended in 10 ml of sterile water and pushed through eh NG tube followed by 10 mL of air to ensure complete administration
Study: NCT04694092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive heart rate control with landiolol
Description: Intensive heart rate control preferably with the use of short-acting betablocker landiolol in combination with digoxin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard approach to heart rate control
Description: Standard heart rate control with intravenous or oral beta-blockers and/or antiarrhythmic in combination with digoxin
Study: NCT02316925

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Setria glutathione supplement
Description: 500 mg/day capsule taken in the morning
Study: NCT02247973

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: bone marrow derived mesenchymal stem cells from related donors.
Study: NCT02316925

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Crystalline Cellulose
Description: 500 mg/day capsule taken in the morning
Study: NCT03134794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention applying the traffic light system (TLS)
Description: The TLS emerged to facilitate consumers' decisions. It has been applyied in medical decision making.
Study: NCT04667832

Intervention type: DIAGNOSTIC_TEST
Intervention: selective coronary artery angiography
Description: Radial approach, invasive selective coronary angiography with selective contrast injection and filming in coronary arteries

Intervention type: DIAGNOSTIC_TEST
Intervention: selective coronary artery angiography
Description: Radial approach, invasive selective coronary angiography with selective contrast injection and filming in coronary arteries
Study: NCT03789604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CS1001 monoclonal antibody
Description: Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CS1001 placebo
Description: Participant will receive CS1001 placebo 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
Study: NCT05012501

Intervention type: DIAGNOSTIC_TEST
Intervention: test NETs markers
Description: NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3), tissue factor, endotoxin, factor X, TAT complex, and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits.
Study: NCT03369782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: rocuronium is administered in bolus and continuous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex is administered just before reduction of the joint

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered as alternative to rocuronium in a bolus and in a syringe pump.~Placebo is administered as alternative to sugammadex
Study: NCT01477567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009385

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00662337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride
Description: After a ten-hour fast and a one-hour fluid restriction prior to each dosing period, subjects received supervised dosing of their first 25 mg treatment with approximately eight ounces of water. Following a seven-day washout, the comparison treatment was administered according to thye same procedure.
Study: NCT02687672

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Transplantation of autologous stem cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Transplantation of autologous stem cells
Study: NCT00938938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Press Guide
Description: The press guide is a 1-page summary of the study findings, written by the investigators.
Study: NCT03473990

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity interval training
Description: 2 minute warm up, followed by 5x1min HIT intervals separated by 90 seconds active recovery (walking on the spot) and then a 2 minute recovery period. The high intensity bouts will be a pyramid of exercises (star jumps, mountain climbers and on-the-spot sprints)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity interval training
Description: 2 minute warm up, followed by 5x1min HIT intervals separated by 90 seconds active recovery (walking on the spot) and then a 2 minute recovery period. The high intensity bouts will be a pyramid of exercises (star jumps, mountain climbers and on-the-spot sprints)
Study: NCT02644044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate
Description: 12.5 mg of methotrexate diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle.
Study: NCT04483765

Intervention type: PROCEDURE
Intervention: spinal anesthesia
Description: patients undergoing transurethral resection of the prostate (TURP) and transurethral resection of the bladder (TURB) surgery under spinal anesthesia.

Intervention type: PROCEDURE
Intervention: spinal anesthesia
Description: patients undergoing transurethral resection of the prostate (TURP) and transurethral resection of the bladder (TURB) surgery under spinal anesthesia.
Study: NCT02505386

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Study: NCT01384877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 10mg/kg by subcutaneous infusion over 5.5 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (D5W)
Description: Same volume as for lidocaine infusion, identical clear liquid in appearance, given in same device over same time period (5.5 hrs)
Study: NCT01677286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg po bid x 12 months
Description: 100mg by mouth twice daily for 1 year.
Study: NCT01258374

Intervention type: DRUG
Intervention: Raltegravir
Description: Raltegravir, 400 mg bid

Intervention type: DRUG
Intervention: Darunavir
Description: Darunavir, 800 mg QD + ritonavir 100 mg QD
Study: NCT00681200

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced health education
Description: health education and social support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation program
Description: The TM program plus didactic-based health education classes
Study: NCT01857752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study: NCT03000972

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cement augmentation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PFN-A Nail

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PFN-A Nail
Study: NCT02378272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care manager for depression
Description: District nurse (care manager for depression) providing clinical services ( in cooperation with GP) as patient information and education on patient's preferred treatment, development of care plan, assessment of patient's depressive symptoms and regular telephone contacts.
Study: NCT01064011

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rt-PA thrombolysis
Description: patients will be administered a total of six doses of rt-PA (each 1 mg/ml) through the external ventricular drain every eight hours.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoscopic hematoma evacuation
Description: In the operating room under general anesthesia, the external ventricular drain will be removed and the burr hole enlarged to allow for entry of the endoscope. The neuroscope will be introduced through the burr hole down the prior external ventricular drain tract into the ipsilateral ventricle. utilizing a standard technique combining gentle aspiration, continuous irrigation, and grasping forceps,the intraventricular hematoma will be evacuated. After the evacuation the endoscope will be removed and an external ventricular drain will be reattached to a closed system and permitted to drain post-operatively.
Study: NCT03243396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy
Description: Eight small-group sessions, including eight children and one guardian for each child, will meet separately, with joint activities in the final three sessions. TF-CBT will be delivered via community health volunteers in the community setting, and via selected teachers in the school setting--with two lay counselors leading the child group, and one leading the guardian group. Most TF-CBT components (psychoeducation, parenting, relaxation, cognitive coping, grief specific skills) will be delivered in groups, but 2-3 individual sessions mid-group will be used for imaginal exposure (i.e., talking about/processing traumatic events).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy
Description: Eight small-group sessions, including eight children and one guardian for each child, will meet separately, with joint activities in the final three sessions. TF-CBT will be delivered via community health volunteers in the community setting, and via selected teachers in the school setting--with two lay counselors leading the child group, and one leading the guardian group. Most TF-CBT components (psychoeducation, parenting, relaxation, cognitive coping, grief specific skills) will be delivered in groups, but 2-3 individual sessions mid-group will be used for imaginal exposure (i.e., talking about/processing traumatic events).
Study: NCT02354326

Intervention type: RADIATION
Intervention: virtual non-calcium dual-energy computed tomography
Description: Undergo VNC DECT
Study: NCT00423631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care and web
Description: A static web site containing cognitive and behavioral self management instructions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care delivered by the primary care provider.
Study: NCT01239485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Chemotherapy: irinotecan, etoposide, and cytarabine daily for 5 days (on days 0, 1, 2, 3, \& 4) -30 min: Atropin ivs 0 hour: irinotecan X mg/m2 in D5W 100 mL IV over 60 min 0 hour: etoposide 100 mg/m2 in x3 N/S mL IV over 60 min 12 hour: cytarabine 2,000 mg/m2 over 3 hr~\*if age ≤ 3 yrs: calculate all drugs in kg base (30kg=1m2) Irinotecan dose is escalated by 25-30% in successive cohorts. The starting irinotecan dose (level 1) is 20 mg/m2/dose on days 0 to 4.
Study: NCT02354326

Intervention type: RADIATION
Intervention: computed tomography
Description: Undergo CT without VNC
Study: NCT02786303

Intervention type: DEVICE
Group type: OTHER
Intervention: Whole-body diffusion- weighted MRI
Study: NCT04576000

Intervention type: DRUG
Intervention: Janus Kinase Inhibitor
Description: Janus Kinase inhibitor induction therapy will be administered according to Standard Of Care (SOC)
Study: NCT03764124

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT imaging
Description: The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events were applied.
Study: NCT01324297

Intervention type: OTHER
Intervention: skin test
Description: four patches of 2 x 3cm thin blotting paper will be soaked with an equivalent amount (0.1 mL) of aqueous methyl nicotinate in four different concentrations: 0.1, 0.01, 0.001, 0.0001 M. The four patches will then be applied at the same time to the inner forearm for 60 seconds.

Intervention type: OTHER
Intervention: skin test
Description: four patches of 2 x 3cm thin blotting paper will be soaked with an equivalent amount (0.1 mL) of aqueous methyl nicotinate in four different concentrations: 0.1, 0.01, 0.001, 0.0001 M. The four patches will then be applied at the same time to the inner forearm for 60 seconds.
Study: NCT01923558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Donepezil Hydrochloride tablets,23 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil Hydrochloride tablets,23 mg
Study: NCT03711721

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food basket

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-Use Therapeutic Food
Study: NCT03151369

Intervention type: DRUG
Group type: OTHER
Intervention: Morphine
Description: patients with the visual analog scale over 3 will receive morphine
Study: NCT00535470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.04% Mechlorethamine gel
Description: Mechlorethamine 0.04% PG applied to affected skin areas (lesions) once daily for up to seven (7) months. The frequency of application may be adjusted for toxicity. After seven (7) months, they will be terminated from the study.
Study: NCT01649765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belimumab 10mg/kg
Description: belimumab 10mg/kg IV monthly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Normal Saline 250 ml
Study: NCT01621074

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: Ergogenic effect

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo effect
Study: NCT02856958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve decompression

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative
Description: Physical therapy
Study: NCT03881683

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HRD and BRCA mutations
Description: Compare BRCA1/2 and HRD genes mutation detected from blood sample (20 ml) and biopsy
Study: NCT01602107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor muscle strengthening exercises
Description: Participants will attend regular physical therapy visits (weekly X 2 weeks, bi-weekly X 4 weeks, and continuing monthly) until the time of their surgery. they will then see the physical therapist for assessment, exercise and advice at 2 and 4 weeks after their surgery. During physical therapy visits, patients will receive two sessions of biofeedback training, and at each visit will work on strength and motor control exercises for their pelvic floor muscles.
Study: NCT01269515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: 90 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: 90 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: 90 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: 90 mg QD
Study: NCT03941951

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non-impositive Program for Optimizing the Use of Antimicrobials
Description: Quasi-experimental intervention through the development of a Program for Optimizing the Use of Antimicrobials in the participating hospitals. The intervention will consist of the development of a consensus guide on the use of new antibiotics, its dissemination in Andalusian hospitals and an audit on the prescription of new antibiotics.
Study: NCT00185965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG 7909
Description: 6 mg intratumoral injection, administered immediately before 2 Gy radiotherapy (RT) to a designated tumor lesion, about 24 hours later after a 2nd 2 Gy RT dose, then weekly for 8 additional weeks (total of 10 injections).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG 7909
Description: 6 mg intratumoral injection, administered immediately before 2 Gy radiotherapy (RT) to a designated tumor lesion, about 24 hours later after a 2nd 2 Gy RT dose, then weekly for 8 additional weeks (total of 10 injections).
Study: NCT01010191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar pill
Study: NCT02093091

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental caries was removed from primary molars and was filled with the recent filling material; Ketac Nano.
Description: Class I carious primary molars were selected. Dental caries was removed and cavities were prepared. The recent nano-filled RMGI filling (Ketac Nano) was used to fill these cavities.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dental caries was removed from primary molars and was filled with the conventional filling material;Vitremer
Description: Class I carious primary molars were selected. Dental caries was removed and cavities were prepared. The conventional RMGI filling (Vitremer) was used to fill these cavities.